Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumors

12 Dec 2014

Abstract excerpt

INTRODUCTION: Wild-type p53 gene is an essential cancer suppressor gene which plays an important role in carcinogenesis and malignant progressions. The p53 gene family participates in almost all the key procedures of cancer biology, such as programmed cell death, angiogenesis, metabolism and epithelial-mesenchymal transition. The mutation or functional defects of the p53 gene family are detected in most of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cancer Research and Treatments
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25496374
DOI: 10.1517/14712598.2015.990882

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumorsPMID 25496374Read ↗

Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncologySemantic proximity Read ↗

Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China.Semantic proximity Read ↗

Advances in adenovirus-mediated p53 cancer gene therapySemantic proximity Read ↗

The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.Semantic proximity Read ↗

Translational approaches targeting the p53 pathway for anti-cancer therapy.Semantic proximity Read ↗

Adenovirus p53 gene therapySemantic proximity Read ↗

Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectivesSemantic proximity Read ↗

Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of CancersSemantic proximity Read ↗

[Detection of p53 gene change and serum antibody level in phase II clinical trial of ad p53 gene therapy].Semantic proximity Read ↗

Gene Therapy Used in Cancer TreatmentSemantic proximity Read ↗

Completed Clinical Trials of p53 Gene Therapy in Cancer: A ClinicalTrials.gov-Based AnalysisSemantic proximity Read ↗

INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.